Post-ICB treatment PDAC infiltrating T cells TCR profile

For the subcutaneous model, 5x105 KPC-Luc cells were injected subcutaneously near the right flank of female C57BL/6 mice. 6-7 days after tumor implantation mice were randomized into 4 treatment groups and treatedwith VIP-R antagonist and/or anti-PD-1. While scram+IgG control mice received scrambled peptide and isotype IgG, the VIP-R antagonist, anti-PD-1 and VIP-R antagonist and anti-PD-1 groups received VIP-R antagonist and IgG; scrambled peptide and anti-PD-1; and VIP-R antagonist and anti-PD-1, respectively. The treatment regimen involved administering 10μg of scrambled or VIP-R antagonist: ANT008, subcutaneously every day and 200μg of IgG or anti-PD-1 intraperitoneally once every three days, for a total of 10 days. 4 groups: control, aPD-1, Ant008, aPD-1+Ant008. 4 samples per each group. 16 samples are analyzed. Sequencing of TCR-β CDR3 V and J sequences performed by Adaptive Biotechnologies (Seattle, WA). >>>Submitter states: Adaptive Biotechnologies does not provide raw data files<<<